{
  "docId": "019de072-e9f7-73aa-b63d-f50108da815f",
  "docSlug": "8dc30a1d33d144ab07b1459d0ae0e445",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 43 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 43,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a donut chart to represent the distribution of HER2 expression levels in breast cancer patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e9f7-73aa-b63d-f50108da815f/11",
  "deckHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f",
  "deckJsonHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f.json",
  "deckAnchorHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "HER2-expression split in breast cancer",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7c03a8c-394c-45f8-8833-faec134befe4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.1,
        "x": 0.87,
        "y": 0.2
      },
      "kind": "image",
      "text": "IHC staining examples 3+, 2+, 1+, <1, 0+",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89f58d08-50b4-4185-af8f-d00197f55451",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "HER2-positive: around 20%; HER2-low: around 50%; HER2-ultralow: potentially 15-30%; HER2-null: potentially 5-20%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57b05b7f-31ed-4709-91b0-ea869ff1ab62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Sources: AstraZeneca data on file; Tarantino P, et al. J Clin Oncol. 2020; Schettini F, et al. NPJ Breast Cancer. 2021; Owens et al., Clinical Breast Cancer 2004; Lambein et al., American Journal of Clinical Pathology 2013, CANcerMPACT 11 (2017); Schettini et al. ESMO BC 2020; Nuciforo et al., Molec Onc. 10, 2016; Scott et al. ASCO 2021 Abstract #1021. HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8aee33aa-9571-4371-80b2-e189f03e7888",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.6,
        "y": 0.2
      },
      "kind": "table",
      "text": "HER2-positive breast cancer (IHC 3+), HER2-low breast cancer (IHC 2+/1+), HER2-ultralow breast cancer (IHC >0 and <1+), HER2-null breast cancer (IHC 0)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f221ece3-4c6a-4847-98d2-4fb042d8b558",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Enhertu: potential for activity across spectrum of HER2 expression",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b203bd5a-4bdf-46ef-a533-7ae1f715b353",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}